25 results about "Receptor specificity" patented technology

The invention belongs to the crossing field of marine biotechnology and bioinformatics, and particularly relates to a method for high-throughput identification of natural functional oligopeptides. At present, bottlenecks still exist in development and application of various functional oligopeptides such as penetrating peptides and antibacterial peptides in non-model species, and the high adaptability of the existing functional oligopeptides in complex and diverse non-model organisms is limited mainly due to differences (amino acid preference and receptor specificity) among species. Therefore, the invention provides a method for high-throughput identification of functional oligopeptides from natural sequences of organisms by means of machine learning. According to the method, based on a biological natural protein sequence, an oligopeptide sequence set meeting a preset length condition is generated through a sliding window strategy system, a deep machine learning model is utilized to perform high-throughput functional prediction on the oligopeptide sequence, and on the basis of performing'interruption-prediction-re-comparison 'on existing functional oligopeptides, the functional oligopeptide sequence set meeting the preset length condition is obtained. The comparison threshold value for accurately identifying the functional oligopeptide can be determined, and the natural functional oligopeptide existing in the protein sequence can be effectively identified based on the threshold value. The functional oligopeptide obtained by the method has strict screening of physicochemical properties of a machine learning model and high-adaptability biological characteristics formed in species evolution. According to the method, the direct application capability of the functional oligopeptide in non-model species is remarkably improved, and an accurate and high-throughput technical means is provided for efficient development and application of the functional oligopeptide in non-model organisms.

The invention discloses an odor receptor gene SinfOR21 of sesamia inferens and application of the odor receptor gene SinfOR21. Belongs to the technical field of biology. According to the invention, sex pheromones of Zhejiang and Guangdong sesamia inferens strains and expression and functional verification of olfaction receptor genes of the sesamia inferens are identified and compared. The method comprises the following steps: firstly, identifying pheromone mixtures with region specificity, and verifying the behavior effectiveness of the pheromone mixtures in field trials; through transcriptome and function analysis, it is proved that a SinfOR21 receptor of the Zhejiang strain is specifically combined with Z11-16: OH, and a homologous receptor of the Guangdong strain does not have the function. And determining that the sex pheromone mixture of the sesamia inferens should be composed of Z11-16: Ac, 16: Ac and Z11-16: Ald. Different from reported sex pheromone mixtures of sesamia zhejiangensis, the sex pheromone mixture of sesamia zhejiangensis is composed of Z11-16: Ac, Z11-16: OH and Z11-16: Ald.

The invention discloses a pilose antler active peptide and application thereof in anti-inflammation, anti-oxidation and anti-aging, and belongs to the technical field of biology. According to the invention, the brand-new active peptide SPLASDLDL screened out from pilose antler for the first time is utilized, and competitive inhibition on TNFR1 is realized through the characteristic that the brand-new active peptide SPLASDLDL is specifically combined with a TNFR1 receptor. A constructed sertoli cell senescence model proves that the polypeptide has anti-inflammatory, anti-oxidation and anti-senescence effects. The invention successfully solves the technical problem that in the prior art, the competitive inhibition TNFR1 targeting peptide cannot be found from pilose antler and the action mechanism of the TNFR1 targeting peptide cannot be clarified, and provides the action mechanism and scientific basis for developing novel anti-inflammatory and anti-aging drugs derived from natural products.

The application discloses a dry-cured ham source oligopeptide and application thereof. The dry-cured ham source oligopeptide comprises at least one of the following amino acid sequences: ELIDQDARDLY, YHEHRSDLN, YKATEPVIAF, INKVEELKKKY and GEKLKRQKY. The dry-cured ham source oligopeptide is applied to preparation of a drug for treating a glycolipid metabolism disorder disease. The extracted and verified oligopeptide can be specifically combined with an AdipoR2 receptor, has stronger glycolipid metabolism regulation activity than a KRQKYD polypeptide, can significantly improve various glycolipid metabolism disorder diseases, and has a good application prospect.

The present disclosure relates to a tumor necrosis factor receptor 2 (TNFR2) agonist polypeptide comprising (i) a TNFR2 binding domain comprising three TNF homologous domains (THDs) that specifically bind to TNFR2; and (ii) an Fc domain. The present disclosure also relates to TNFR2 agonists for use in the treatment and / or prevention of e.g. Chronic pain or multiple sclerosis.

The invention discloses a polypeptide for promoting collagen synthesis and application thereof. The polypeptide capable of promoting collagen synthesis is specifically combined with a receptor TbetaR II to regulate collagen synthesis in fibroblasts, and is a TGF-beta mimic peptide analogue. And the TB2 has a proliferation effect on BALB / 3T3 cells. The TB2 can promote the expression of collagen related factors Collagen I, Collagen III, Smad3 and MAPK, and has the effects of promoting cell migration and promoting wound healing. Therefore, the polypeptide for promoting collagen synthesis provided by the invention can be used for preparing a preparation for promoting cell proliferation or collagen generation.

Some aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on a muscle cell. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or an RNAi oligonucleotide.

The present application relates to the technical field of biological medicine, in particular to a functionalized targeted liposome and application thereof, comprising: lipids and a targeting ligand; wherein the targeting ligand can specifically bind to a TREM2 receptor. The liposome of the present application can specifically bind to the TREM2 receptor by means of the targeting ligand, realize precise targeting of cells containing the TREM2 receptor on the surface, ensure direct action on target cells, and further improve the precision of delivered substances. The liposome has targeting property, high stability, small side effects, and can be applied to the development of drug carriers, pharmaceutical compositions, etc., and has a wide application prospect. For example, the liposome of the present application is dynamically connected with a hydrogel molecule by a borate ester bond to prepare a hydrogel pharmaceutical composition containing the functionalized targeted liposome of the present application. The hydrogel pharmaceutical composition can release the liposome of the present application according to the change of pH and ROS in the surrounding environment in response to an inflammatory environment, and target cells containing the TREM2 receptor on the surface, i.e. microglial cells (having the TREM2 receptor on the surface), by virtue of the targeting ligand exposed on the surface, and regulate the polarization state of the cells, inhibit the polarization of the cells to the pro-inflammatory M1 type, and promote the polarization of the cells to the anti-inflammatory M2 type, thereby improving the local microenvironment of the spinal cord injury site and promoting nerve regeneration.

The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed cancer testis antigen preferentially expressed antigen in melanoma (FRAME) peptide, as well as therapeutic and diagnostic methods of using those isolated TCRs.

The invention discloses a device suitable for aerosol phase virus-receptor affinity and activity evaluation, an evaluation method and a data analysis method. The device comprises an aerosol generation unit, a bionic artificial cell array unit, an environment control and fixing assembly and an activity evaluation and collection unit. The method is characterized in that through a micro-nano processing and molecular self-assembly technology, a supporting lipid double-layer membrane is constructed on an array substrate, receptor protein is directionally fixed, and a bionic cell interface is formed. When in use, a virus sample is atomized into aerosol and flows through the interface, so that the virus is specifically combined with the receptor; affinity parameters in an aerosol environment can be obtained by combining quantitative detection with viruses and utilizing algorithm model fitting. Meanwhile, the system can directly collect an aerosol sample after action and inoculate cells for culture, so that synchronous verification of virus biological infection activity is realized. The device is easy and convenient to operate and high in universality, and a brand new tool is provided for studying the recognition and infection mechanism of viruses under the real aerosol transmission condition.

Provided is use of an HPCAL1 protein in enhancing cardiac function. The HPCAL1 protein can specifically bind to a recombinant β3-adrenergic receptor, and can be used as a β3-adrenergic receptor antagonist protein. It is found in animal experiments that by intravenously injecting recombinant mouse HPCAL1 with a certain concentration into an ischemia-reperfusion mouse model, the cardiac function of the mice can be effectively improved, and the ejection fraction of the mice is enhanced, indicating that the HPCAL1 protein can be used for enhancing the cardiac function and has potential medicinal value for treating cardiovascular diseases with cardiac function decline. Moreover, the HPCAL1 protein is a class of biomacromolecules with low toxicity, which solves the problem of high hepatic and renal toxicity of small molecule chemical drugs. Therefore, the HPCAL1 protein has relatively high application value.

This invention provides the application of cyperene in the preparation of olfactory receptor Olfr43 specific agonist drugs, relating to the field of small molecule pharmaceutical technology of traditional Chinese medicine. This invention constructs Hana3A... Olfr43‑FLuc‑RLuc A heterologous OR dual-luciferase screening platform revealed that cyperene can activate the downstream pathway of the olfactory receptor Olfr43, significantly increasing intracellular cAMP levels. Cellular experiments further verified that cyperene stimulation significantly increased the mNRA and protein expression levels of Olfr43 in cells, raising downstream cAMP levels. This, in turn, inhibited the expression of lipid synthesis-related genes by phosphorylating CREB, promoting HES-1, and inhibiting DGAT2 protein expression, ultimately reducing TC and TG in the HepG2 hyperlipidemia model. This invention is the first to propose that cyperene can act as a specific agonist targeting the olfactory receptor Olfr43 to regulate downstream cAMP changes. This invention provides a new option for the development of highly effective agonists specifically targeting Olfr43 / OR1A1.

The present invention provides compounds that specifically bind to one or more Wnt receptors and methods related thereto. In some aspects, compositions and methods are provided for treating eye disorders by regulating the Wnt signaling pathway. In particular, the eye disorder is retinopathy. Also provided are administration methods and pharmaceutical compositions.

Some embodiments of the methods and compositions provided herein include cells having membrane-tethered, IL13 mutein-directed zetakine receptors, such as those which specifically bind to the IL-13 receptor alpha 2 (IL13Ra2) at a 50-fold higher affinity than wildtype IL-13, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors, using these compositions. In some embodiments, the receptors include spacer regions, such as particular spacer regions designed to provide certain advantages.

The invention discloses an X-ray response type neutrophile granulocyte loaded nanometer vitepofen and an application thereof. According to the invention, a solvent-anti-solvent method is combined with a hydrothermal method to prepare the nano vitepofen. The nanometer vitepofen can adsorb part of protein in plasma in vivo, and a'protein crown 'layer is formed on the surfaces of particles. The adsorbed complement C3 can be specifically combined with a CR3 receptor on the surface of the activated neutrophil, and proteins such as fibrinogen and the like can be combined with an integrin receptor on the surface of the neutrophil, so that the nano vitepofen is delivered to a tumor focus in a targeted manner by utilizing the inflammatory chemotactic characteristic of the neutrophil. Moreover, the nano vitepofen has an X-ray response characteristic, and can generate active oxygen in tumor cells under X-ray irradiation and induce the tumor cells to generate immunogenic death, so that the anti-tumor immune response of an organism is triggered, the radiotherapy curative effect is enhanced, and the radiotherapy sensitization is realized.

The present disclosure provides antibodies and polypeptides that specifically bind to killer cell lectin-like receptor G1 (KLRG1). Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating subjects using these antibodies.

The application belongs to the technical field of biological medicine, and particularly relates to a VEGFR3 receptor specific binding peptide and application thereof, wherein the amino acid sequence of the VEGFR3 receptor specific binding peptide is shown as SEQ ID NO. 1. The VEGFR3 receptor specific binding peptide can specifically bind with the VEGFR3 receptor on the cell membrane, thereby activating a downstream signal path, stimulating the migration and proliferation of lymphatic endothelial cells, forming a new lymphatic network, and increasing the permeability of the lymphatic vessel, thereby providing convenience for the flow of lymph fluid and further promoting the function of the lymphatic vessel. The VEGFR3 receptor specific binding peptide not only has a significant effect of promoting the proliferation and migration of human lymphatic endothelial cells, but also shows good biocompatibility and biological activity. In addition, the VEGFR3 receptor specific binding peptide can also promote the proliferation and migration of human umbilical vein endothelial cells.

The invention discloses a mitochondrial targeting nano-composite. The mitochondrial targeting nano-composite is formed by a mitochondrial targeting HPMA polymer-drug conjugate with positive charges and hyaluronic acid with negative charges through electrostatic self-assembly, the mitochondrial targeting HPMA polymer-drug conjugate is a conjugate formed by connecting an HPMA polymer modified by a mitochondrial targeting group DEA and a mitochondrial metabolism inhibitor through a cleavable bond. The invention further discloses a preparation method of the mitochondrial targeting nano-composite and application of the mitochondrial targeting nano-composite in preparation of anti-tumor drugs. According to the invention, hyaluronic acid is specifically combined with a CD44 receptor highly expressed on the surface of a tumor cell, so that active targeting at the tumor cell level is realized; meanwhile, by means of a DEA or GPMA mitochondrial targeting group, the drug is guided to be accurately positioned to tumor cell mitochondria, a dual targeting system of cell targeting and organelle targeting is formed, the enrichment concentration of the drug at an action target spot is greatly improved, and the problems that a traditional drug is weak in targeting property and low in action efficiency are solved.

The invention discloses a tumor cell exosome simulation nano sound-sensitive agent as well as a preparation method and application thereof, and belongs to the technical field of tumor treatment. The nano sound-sensitive agent is formed by compounding MnCO3 particles, BPTES and an exosome membrane, and CD63 protein contained on the surface of the exosome membrane can be specifically combined with a CD9 receptor overexpressed on the surface of a tumor cell, so that tumor targeted delivery is realized. The nano sound-sensitive agent can release MnCO3 and BPTES under the triggering of ultrasonic irradiation: MnCO3 has the function of the sound-sensitive agent, can generate singlet oxygen as a core component of active oxygen, and can catalyze H2O2 in a tumor microenvironment through peroxidase-like activity to generate. OH; bPTES can inhibit the activity of glutaminase and block a glutathione synthesis pathway, so that the scavenging capacity of GSH on active oxygen is weakened, and the tumor killing efficiency of the active oxygen is remarkably enhanced. The invention provides a brand-new technical scheme and strategy support for precise treatment of tumors.

Disclosed in the present invention are a synthetic T cell receptor antigen receptor specifically binding to LILRB4 and the use thereof. In the present invention, TCR and CAR are modified by means of targeting the antigen binding fragment of LILRB4, so that a better effect on tumor treatment is obtained.

Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and / or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and / or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and / or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.

The application provides a kind of dual-specificity nucleic acid aptamer, derivative, preparation method and its application, the nucleic acid aptamer includes first nucleic acid sequence, second nucleic acid sequence;First nucleic acid sequence includes target receptor specificity nucleic acid aptamer and first connecting part, and second nucleic acid sequence includes pairing receptor specificity nucleic acid aptamer and second connecting part;Target receptor specificity nucleic acid aptamer can be specifically combined with target receptor, and pairing receptor specificity nucleic acid aptamer can be specifically recognized with pairing receptor;First connecting part and second connecting part form connecting structure.Thereby, two nucleic acid aptamers can form stable dual-specificity nucleic acid aptamer structure.The dual-specificity nucleic acid aptamer and its derivative can hinder the binding and activation of ligand to target receptor, thereby further affecting cell function.The technical scheme of the application improves the regulation efficiency of nucleic acid aptamer on receptor and cell function.

Some embodiments of the methods and compositions provided herein include cells having membrane-tethered. IL13 mutein-directed zetakine receptors, such as those which specifically bind to the IL-13 receptor alpha 2 (IL13Ra2) at a 50-fold higher affinity than wild-type IL-13, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors, using these compositions. In some embodiments, the receptors include spacer regions, such as particular spacer regions designed to provide certain advantages.

The present application belongs to the technical field of genetic engineering and protein engineering, and relates to a site-directed mutant sucrose phosphorylase and application thereof. The site-directed mutant sucrose phosphorylase is obtained by making a point mutation in sucrose phosphorylase (BiSPase) with an amino acid sequence shown as SEQ ID NO. 1, and the mutation site of the point mutation is selected from the 141th and / or 197th. Preferably, the point mutation of the 141th is threonine mutated into cysteine; and the point mutation of the 197th is glycine mutated into cysteine. The catalytic efficiency of the sucrose phosphorylase variant enzyme provided by the present application is obviously improved, so that the yield of L-ascorbyl glucoside can be improved, the production cost is reduced, the problems of low receptor specificity and low enzyme activity of sucrose phosphorylase in the prior art are solved, and the sucrose phosphorylase has a wide industrial application prospect.

Receptor-specific cyclic peptides of the formulawhere Xaa1, Xaa2, Xaa3, x, R1, R2, R3 and R4 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating, or treating melanocortin receptor-mediated diseases, indications, conditions, and syndromes utilizing melanocortin receptor-specific cyclic peptides of formula I.